Cantor Fitzgerald Increases ADMA Biologics (NASDAQ:ADMA) Price Target to $15.00

ADMA Biologics (NASDAQ:ADMAGet Free Report) had its price objective boosted by Cantor Fitzgerald from $10.00 to $15.00 in a report issued on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 25.00% from the stock’s current price.

Several other equities analysts also recently commented on the stock. Raymond James upped their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the company a “strong-buy” rating in a report on Friday, May 10th. Mizuho upped their price target on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Thursday, June 20th. Finally, HC Wainwright upped their price target on shares of ADMA Biologics from $7.50 to $10.00 and gave the company a “buy” rating in a report on Friday, May 10th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, ADMA Biologics has a consensus rating of “Buy” and an average target price of $12.25.

Check Out Our Latest Stock Report on ADMA

ADMA Biologics Stock Up 0.3 %

Shares of NASDAQ ADMA opened at $12.00 on Tuesday. The firm’s 50-day moving average price is $9.92 and its 200-day moving average price is $7.12. The company has a current ratio of 5.21, a quick ratio of 1.86 and a debt-to-equity ratio of 0.91. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of -600.00 and a beta of 0.55. ADMA Biologics has a 12-month low of $3.06 and a 12-month high of $12.15.

ADMA Biologics (NASDAQ:ADMAGet Free Report) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.05 by $0.03. The company had revenue of $81.90 million for the quarter, compared to the consensus estimate of $77.28 million. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. The firm’s revenue was up 43.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.03) EPS. On average, equities research analysts anticipate that ADMA Biologics will post 0.35 EPS for the current fiscal year.

Insider Activity at ADMA Biologics

In related news, CEO Adam S. Grossman sold 100,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $10.72, for a total transaction of $1,072,000.00. Following the transaction, the chief executive officer now directly owns 2,081,475 shares of the company’s stock, valued at $22,313,412. The sale was disclosed in a filing with the SEC, which is accessible through this link. 3.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ADMA Biologics

Institutional investors have recently bought and sold shares of the company. Alberta Investment Management Corp boosted its stake in ADMA Biologics by 32.4% in the fourth quarter. Alberta Investment Management Corp now owns 460,774 shares of the biotechnology company’s stock valued at $2,083,000 after acquiring an additional 112,831 shares in the last quarter. GSA Capital Partners LLP boosted its stake in ADMA Biologics by 87.7% in the third quarter. GSA Capital Partners LLP now owns 242,284 shares of the biotechnology company’s stock valued at $867,000 after acquiring an additional 113,184 shares in the last quarter. American Century Companies Inc. boosted its stake in ADMA Biologics by 20.8% in the third quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company’s stock valued at $17,514,000 after acquiring an additional 840,761 shares in the last quarter. SG Americas Securities LLC boosted its stake in ADMA Biologics by 417.3% in the fourth quarter. SG Americas Securities LLC now owns 93,236 shares of the biotechnology company’s stock valued at $421,000 after acquiring an additional 75,213 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in ADMA Biologics by 49.8% in the fourth quarter. BNP Paribas Financial Markets now owns 290,605 shares of the biotechnology company’s stock valued at $1,314,000 after acquiring an additional 96,653 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

About ADMA Biologics

(Get Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Read More

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.